
Faced with geopolitics and trade war, U.S. companies in China report record-low new investment plans
WASHINGTON — American companies in China are reporting record-low new investment plans for this year and declining confidence in profits, while uncertainty in U.S.-China relations and President Donald Trump's tariffs have become their top concerns, according to a business survey released Wednesday.
The companies are also challenged by China's slowing economy, where weak domestic demand and overcapacity in local industries are eroding profitability for the Americans.
'Businesses in China are less profitable now than they were years ago, but risks, including reputational risk, regulatory risk, and political risk, are increasing,' said Sean Stein, the president of the U.S.-China Business Council, a Washington-based group that represents American companies doing business in China, including major multinationals.
The survey, conducted between March and May and drawing from 130 member companies, came after the two countries clashed over tariffs and non-tariff measures, including export controls on critical products such as rare-earth magnets and advanced computer chips. Following high-level talks in Geneva and London, U.S. and Chinese officials agreed to pull back from sky-high tariffs and restrictions on exports, but uncertainty persists as the two sides are yet to hammer out a more permanent trade deal.
Kyle Sullivan, vice president of business advisory services at the USCBC, said more than half of the companies in the survey indicated they do not have new investment plans in China 'at all' this year.
'That's a record high,' Sullivan said, noting that it is ''a new development that we have not observed in previous surveys.'
Around 40 per cent of companies reported negative effects from U.S. export control measures, with many experiencing lost sales, severed customer relationships, and reputational damage from being unreliable suppliers, according to the survey. Citing national security, the U.S. government has banned exports to China of high-tech products, such as the most advanced chips, which could help boost China's military capabilities.
Stein argued that export controls must be very carefully targeted, because businesses from Europe or Japan, or local businesses in China would immediately fill the void left by American companies.
Silicon Valley chipmaker Nvidia won approval from the Trump administration to resume sales to China of its advanced H20 chips used to develop artificial intelligence, its CEO Jensen Huang announced on Monday, though the company's most powerful chips remain under U.S. export control rules.
While 82 per cent of U.S. companies reported profits in 2024, fewer than half are optimistic about the future in China, reflecting concerns over tariffs, deflation, and policy uncertainty, according to the survey.
Also, a record high number of American businesses plan to relocate their business operations outside of China, Sullivan said, as 27 per cent of the members indicated so, up from 19 per cent the year before.
In a departure from past surveys, concerns over China's regulatory environment, including risks of intellectual property misuse and lack of market access, didn't make it to the top five concerns this year. That's likely a first, and not for a good reason, Stein said.
'It is not because things got dramatically better on the Chinese side, but the new challenges, often coming from the U.S., are now posing as much of a challenge,' Stein said.
Almost all the American companies said they cannot remain globally competitive without their Chinese operations.
A survey from the European Union Chamber of Commerce in China in May found that European companies were cutting costs and scaling back investment plans in China as its economy slows and fierce competition drives down prices.
---
Fu Ting, The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
38 minutes ago
- Globe and Mail
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
Johnson & Johnson JNJ delivered strong second-quarter 2025 results, with both the top and bottom lines exceeding expectations. Despite the loss of exclusivity ('LOE') of its multi-billion-dollar product, Stelara, J&J's Innovative Medicines unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato contributed significantly to growth. Importantly, its MedTech segment also outperformed expectations. Sales in the MedTech segment improved from the first-quarter levels, driven by strong momentum in Cardiovascular, Surgery and Vision segments despite continued headwinds in China. J&J also raised its sales and EPS guidance for the year to reflect a strong operational performance coupled with currency tailwinds. The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90, driven by top-line strength, favorable impact of foreign currency and lowered tariff impact. J&J halved its expectations for tariff-related costs this year from $400 million to $200 million. The tariff costs are exclusively related to its MedTech unit. In response to the earnings beat and guidance raise, J&J's shares rose more than 6% on July 16, reflecting investors' renewed optimism for the stock. However, a single quarter's results are not so important for long-term investors, and the focus should rather be on the company's strong fundamentals. Let's understand the company's strengths and weaknesses to better analyze how to play J&J stock in the post-earnings scenario. J&J's Diversified Business Model Johnson & Johnson's biggest strength lies in its diversified business model as it is the only major health care company operating in both the medical devices and pharmaceutical sectors. In 2023,J&J separated its Consumer Health business into a newly listed company called Kenvue KVUE. The separation of Kenvue allowed J&J to focus on its core pharmaceutical and medical device business. It has more than 275 subsidiaries, indicating that the business is extremely well-diversified. This diversification helps withstand economic cycles more effectively. J&J has 26 platforms with annual sales exceeding $1 billion. Its diversified business is allowing it to post top-line growth in 2025, despite LOE for a blockbuster drug like Stelara. Meanwhile, it has one of the largest R&D budgets among pharma companies. JNJ's Innovative Medicine Unit: A Bright Spot J&J's Innovative Medicine unit is showing a growth trend. The segment's sales rose 2.4% in the second quarter of 2025 on an organic basis despite LOE for Stelara and the negative impact of the Part D redesign. J&J expects continued growth in the second half of 2025 to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada as well as new drugs like Carvykti, Tecvayli and Talvey and new indications for Tremfya and Rybrevant. J&J expects to generate more than $57 billion in sales in the Innovative Medicines segment in 2025. It expects the Innovative Medicine business to grow 5% to 7% from 2025 to 2030. J&J mentioned on the second-quarter conference call that it expects its oncology sales to be more than $50 billion by 2030 — quite an optimistic target in our view. Moreover, J&J believes 10 of its new Innovative Medicine products have the potential to deliver peak sales of $5 billion, including new cancer drugs like Talvey and Tecvayli, a newly acquired drug, Caplyta and pipeline candidates like nipocalimab, TAR-200 and icotrokinra (JNJ-2113). Nipocalimab was approved under the name Imaavy in April for treating generalized myasthenia gravis. TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. Caplyta was added with the Apil acquisition of Intra-Cellular Therapies. J&J's MedTech Segment Shows Improvement in Q2 J&J's MedTech segment sales rose 6.1% on an operational basis in the second quarter, improving from the first-quarter levels, driven by the newly acquired cardiovascular businesses, Abiomed and Shockwave, as well as in Surgical Vision and wound closure in Surgery. Moreover, improvements in J&J's electrophysiology business also drove sequential growth. In the MedTech segment, increased adoption of newly launched products in Cardiovascular, Surgery and Vision is likely to drive growth in the second half. Sales are expected to be higher in the second half than the first half as the business moves past tougher first-half comps and new products gain momentum throughout 2025. However, the company continues to face headwinds in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program. VBP is a government-driven cost containment effort in China. J&J expects continued impacts from VBP issues in China in 2025 as the program continues to expand across provinces and products. Patent Expiration of J&J's Blockbuster Drug Stelara & Other Headwinds J&J lost U.S. patent exclusivity of Stelara in 2025. The drug generated sales of $10.36 billion in 2024. The launch of generics is significantly eroding the drug's sales and hurting J&J's sales and profits in 2025. Stelara sales declined 42.7% in the second quarter of 2025. Several biosimilar versions of Stelara have been launched in the United States in 2025. According to patent settlements and license agreements, Amgen AMGN, Teva Pharmaceutical Industries TEVA, Samsung Bioepis/Sandoz and some other companies have already launched Stelara biosimilars this year. Stelara biosimilar competition is expected to accelerate throughout 2025 as the number of biosimilar entrants increases. In addition, sales in 2025 are being hurt by the impact of the Medicare Part D redesign. J&J's Talc Suits & Pharma Tariffs Remain an Overhang J&J faces more than 62,000 lawsuits for its talc-based products, primarily baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer. J&J insists that its talc-based products are safe and do not cause cancer. The company permanently discontinued the sales of its talc-based Johnson's Baby Powder. In April, a bankruptcy court in Texas rejected J&J's proposed bankruptcy plan to settle its talc lawsuits after a two-week trial in Houston. J&J will go back to the traditional tort system to fight the lawsuits individually with its bankruptcy strategy to settle the lawsuits failing for the third time. The uncertainty around tariffs and trade production measures has muted economic growth. President Trump has once again threatened to impose heavy tariffs, as high as 200%, on pharmaceutical imports. Trump's repeated threats to impose tariffs on pharmaceutical imports are aimed at pushing American pharma companies to shift pharmaceutical production back to the United States, primarily from European and Asian countries. Trump has said that drugmakers have about one to one and a half years to bring production back to the United States before the new tariffs are imposed. J&J has already committed to boosting manufacturing in the United States and has a plan to invest $55 billion over the next four years to ensure that all medicines consumed in the United States are manufactured domestically. J&J Stock Price, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 15.1% in the year-to-date period against a 0.5% decline for the industry. The stock has also outperformed the sector and the S&P 500 Index, as seen in the chart below. JNJ Stock Outperforms Industry, Sector & S&P 500 From a valuation standpoint, J&J is slightly expensive. In terms of the price/earnings ratio, the company's shares currently trade at 14.74 forward earnings, slightly higher than 14.71 for the industry. The stock is, however, trading below its five-year mean of 15.70. JNJ Stock Valuation The Zacks Consensus Estimate for 2025 earnings has risen from $10.64 per share to $10.83 over the past seven days, while that for 2026 has risen from $11.09 to $11.33 over the same timeframe. JNJ Estimate Movement Consider Investing in J&J's Stock J&J considers 2025 to be a 'catalyst year,' positioning the company for growth in the second half of the decade. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. While newly launched products should drive growth in the Innovative Medicines segment in the second half, the MedTech segment may benefit from new products and easier comps. J&J expects growth to accelerate from 2026 onward. J&J is also rapidly advancing its pipeline, attaining significant clinical and regulatory milestones that will help drive accelerating growth through the back half of the decade. J&J has also been on an acquisition spree, with the latest acquisition of Intra-Cellular Therapies strengthening its presence in the neurological and psychiatric drug market. In April, J&J's board authorized a 4.8% increase in its quarterly dividend, marking the company's 63rd consecutive year of dividend increase. The Stelara patent cliff and the potential impact of Part D redesign will be significant headwinds in 2025. The uncertainty around the talc lawsuits and pharma tariffs lingers. However, the company looks quite confident that it will be able to navigate these challenges. The stock's price appreciation this year, attractive valuation and rising estimates should encourage investors to bet on this Zacks Rank #2 (Buy) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. One Big Gain, Every Trading Day To help you take full advantage of this market, you're invited to access every stock recommendation in all our private portfolios - for just $1. Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That's about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%. Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report Kenvue Inc. (KVUE): Free Stock Analysis Report


Globe and Mail
an hour ago
- Globe and Mail
Hydrogen Energy Storage Market Set to Surpass USD 17.50 Billion by 2025, Driven by Renewable Energy Integration
The global hydrogen energy storage market is estimated to be valued at USD 17.50 Bn in 2025 and is expected to reach USD 24.32 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.8% from 2025 to 2032. The hydrogen energy storage market is experiencing strong growth driven by rising demand for sustainable energy solutions and the urgent need to decarbonize energy-intensive industries. Countries like China, India, and others are actively promoting hydrogen technologies and infrastructure through supportive policies and public funding to achieve their decarbonization targets. Both utility-scale initiatives and behind-the-meter distributed hydrogen storage systems are gaining significant momentum. Global Hydrogen Energy Storage Market Key Takeaways According to Coherent Market Insights (CMI), the global hydrogen energy storage market size is poised to expand at a CAGR of 4.8%, reaching USD 17.50 Bn in 2025 and USD 24.32 Bn by 2032. Compressed hydrogen storage is set to remain highly sought-after technology, accounting for nearly two-fifths of the global hydrogen energy storage market share in 2025. Power generation is expected to be the most lucrative application for hydrogen energy storage, generating about USD 5.96 Bn in market revenue by 2025. North America leads the global hydrogen energy storage industry, accounting for 36.1% market share in 2025. Asia Pacific is projected to emerge as a hotbed for hydrogen energy storage companies during the forecast period. Renewable Energy Integration Spurring Market Growth Coherent Market Insights' latest hydrogen energy storage market analysis highlights major factors driving industry growth. Increasing integration of renewable energy sources is one such key factor. Renewable energy sources like solar and wind are inherently intermittent. This intermittency is putting storage technologies like hydrogen energy storage into limelight, helping companies address these fluctuations. Hydrogen storage provides an effective solution by storing excess energy produced during periods of high generation and releasing it during periods of low generation. This helps balance supply and demand as well as enhances grid stability and supports the global transition to low-carbon energy systems. Buy this Complete Business Research Report: High Production Costs and Alternative Technologies Limiting Market Growth The future hydrogen energy storage market outlook looks optimistic. However, high production costs and competition for alternative technologies may constrain its growth during the forecast period. Green hydrogen, produced through electrolysis using renewable energy, remains more expensive than hydrogen derived from fossil fuels. This cost barrier poses a major challenge and could hinder the hydrogen energy storage market growth. In addition, alternative storage technologies like battery energy storage systems (BESS) and pumped hydro storage are gaining traction due to their cost-effectiveness and other benefits. Growing adoption of these alternatives may limit hydrogen energy storage market demand during the forthcoming period. Strong Decarbonization Efforts Unlocking New Growth Opportunities Governments and industries in the contemporary world are increasingly investing in hydrogen to reduce carbon emissions and achieve ambitious net-zero targets. This growing focus on decarbonization is expected to drive demand for hydrogen energy storage technologies, creating lucrative growth opportunities for the industry. Hydrogen energy storage plays a critical role in supporting clean energy transitions across the transportation, power generation, and industrial sectors. As clean energy investments rise, hydrogen energy storage is set to become a key low-carbon enabler, boosting market growth. Impact of AI on the Hydrogen Energy Storage Market Artificial intelligence (AI) is gradually making its way into the hydrogen energy storage market. It assists companies in enhancing operational efficiency, predictive maintenance, and system optimization. AI-driven analytics enable real-time monitoring of hydrogen production, storage, and distribution. This leads to improved energy management and reduced operational costs. Machine learning algorithms also support development of smart hydrogen grids, forecasting demand, and optimizing supply chains. This integration of AI fosters scalability and reliability in hydrogen infrastructure, accelerating the adoption of hydrogen as a clean energy source. Emerging Hydrogen Energy Storage Market Trends Rising demand for clean mobility solutions is a key trend in the hydrogen energy storage market. Hydrogen energy storage supports the electrification of the transport sector. It is especially important for fuel cell electric vehicles (FCEVs) as they rely on hydrogen refueling infrastructure. Continuous advancements in electrolyzer technologies are driving down hydrogen production costs, improving the overall economic feasibility of hydrogen energy storage. These innovations are expected to create new growth opportunities for manufacturers of hydrogen energy storage technologies and related infrastructure. Rise in green hydrogen projects is expected to propel demand for hydrogen storage solutions. Many countries are investing in large-scale green hydrogen initiatives as part of their broader shift toward renewable and low-carbon energy sources. This trend is likely to accelerate the adoption and sales of hydrogen energy storage technologies during the forecast period. There is a growing trend of using hydrogen in industries like metal refining and oil refining, as these sectors aim to reduce greenhouse gas emissions. This decarbonization drive is expected to increase demand for clean hydrogen and associated energy storage solutions. Analyst's View 'The global hydrogen energy storage industry is poised to grow steadily, owing to increasing integration of renewable energy sources, strong decarbonization efforts, rising demand for clean mobility solutions, and ongoing technological advancements,' said a senior analyst at CMI. Current Events and Their Impact on the Hydrogen Energy Storage Market Competitor Insights Key companies in the hydrogen energy storage market research report: - Linde plc - ITM Power - First Hydrogen - Messer Group - Nel Hydrogen - Siemens Energy - Shell - Hydrogenics (Cummins) - Air Liquide - Lhyfe - HySiLabs - TotalEnergies - H2 Storage - Engie - BP - ExxonMobil - Ceres Media - Orsted - Plug Power - Hyzon Motors Key Developments In August 2024, Uniper opened a new storage facility for green hydrogen at Krummhornt. The facility is Germany's first hydrogen storage site in a former natural gas cavern. In August 2024, Linde Engineering signed an agreement with Shell to construct a 100 MW renewable hydrogen plant for the REFHYNE II project. Linde will take full responsibility for the engineering, procurement, and construction of a new proton exchange membrane (PEM) hydrogen electrolysis facility. In July 2024, Messer announced plans to build a new green hydrogen plant in collaboration with the district of Duren. The green hydrogen produced is intended primarily to power fuel-cell buses in the Düren district.


CTV News
an hour ago
- CTV News
UN ‘concerned' as Afghan women arrested over Taliban dress code
A Taliban fighter stands guard in a market ahead of Eid al-Adha, or "Feast of the Sacrifice", in Kabul, Afghanistan, Thursday, June 5, 2025. (AP Photo/Ebrahim Noroozi) The United Nations expressed its 'concern' on Monday over a series of arrests of Afghan women in the capital Kabul who were accused of breaching the Taliban government's strict dress code, with officials denying such detentions. Since their return to power in 2021, the Taliban authorities have imposed a severe interpretation of Islamic law and require all women to be covered from head to toe. The UN Assistance Mission in Afghanistan (UNAMA) said it was 'concerned by the arrest of numerous women & girls in Kabul between 16-19 July due to their alleged non-compliance with the de facto authorities' hijab instructions'. 'These incidents serve to further isolate women and girls, contribute to a climate of fear, and erode public trust,' the agency wrote on X, adding that they had contacted the authorities about the matter. A witness told AFP last week that while driving in central Kabul, he saw a unit of the Ministry for Promotion of Virtue and Prevention of Vice (PVPV) 'telling two women to go with them in the car'. The women were wearing flowing abaya robes and wearing make-up. They resisted getting into the vehicle but were forced to do so by a PVPV official who was holding a gun, the witness said on condition of anonymity. The Taliban authorities denied the arrests and said they have 'only campaigned for (the) hijab' dress code. 'But there's nothing like arresting someone or taking anyone to jail,' PVPV spokesman Saiful Islam Khyber told AFP. Over the past four years, women have been progressively isolated by the Taliban authorities, which have banned them from universities, public parks, gyms and beauty salons, in what the UN has denounced as 'gender apartheid'. The Taliban government says that their interpretation of Islamic law 'guarantees' everyone's rights and that allegations of discrimination are 'unfounded'. On Monday, UNAMA called on the Taliban authorities 'to rescind policies and practices that restrict women and girls' human rights and fundamental freedoms'.